Corbus Pharmaceuticals Holdings (CRBP) stock: insider trades, news & valuation
Net sellingShare price and insider trades
Corbus Pharmaceuticals Holdings insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $126K and 9 sold $1.7M of CRBP stock on the open market.
Get emailed when insiders cluster-buy stocks like CRBP
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
CRBP insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $25K | 1 | $308K | 3 |
| Q2 2026 | $101K | 2 | $73K | 3 |
| Q1 2026 | — | 0 | $247K | 6 |
| Q4 2025 | — | 0 | $1.1M | 5 |
Valuation, profit and volume
Summary
Over the past 12 months, 1 Corbus Pharmaceuticals Holdings, Inc. insider reported open-market purchases totaling $126K, while 9 insiders reported sales totaling $1.7M. 12 of 17 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 15SEC | Yong BenDirector | Sell Plan | 2,0009,383 held (−18%) | $7.84 | $16K | -31.4% | — |
| Aug 12SEC | Nishant C SaxenaChief Business Officer | Buy | 2,60077,900 held (+3%) | $9.63 | $25K | -44.1% | — |
| Aug 10SEC | Yuval CohenCEO | Sell Plan | 17,000157,316 held (−10%) | $10.08 | $171K | -46.6% | — |
| Aug 10SEC | Sean F. MoranCFO | Sell Plan | 12,00084,694 held (−12%) | $10.08 | $121K | -46.6% | — |
| Jun 11SEC | John Kenneth JenkinsDirector | Sell Plan | 4,8003,833 held (−56%) | $7.91 | $38K | -32.0% | — |
| Jun 11SEC | Anne AltmeyerDirector | Sell Plan | 2,4127,579 held (−24%) | $7.91 | $19K | -32.0% | — |
| Jun 11SEC | Winston KungDirector | Sell Plan | 2,02612,140 held (−14%) | $7.91 | $16K | -32.0% | — |
| Jun 3SEC | Nishant C SaxenaChief Business Officer | Buy | 9,00075,300 held (+14%) | $7.58 | $68K | -29.0% | — |
| Jun 3SEC | Nishant C SaxenaChief Business Officer | Buy | 4,50066,300 held (+7%) | $7.33 | $33K | -26.6% | — |
| Mar 4SEC | Dominic SmethurstChief Medical Officer | Sell | 6,09789,790 held (−6%) | $8.30 | $51K | -35.2% | — |
| Feb 18SEC | Yuval CohenCEO | Sell Plan | 13,871174,316 held (−7%) | $7.78 | $108K | -30.8% | — |
| Feb 18SEC | Sean F. MoranCFO | Sell Plan | 4,70196,694 held (−5%) | $7.78 | $37K | -30.8% | — |
| Feb 18SEC | Ian HodgsonCOO | Sell | 84751,080 held (−2%) | $7.38 | $6K | -27.1% | — |
| Feb 4SEC | Dominic SmethurstChief Medical Officer | Sell | 3,28595,887 held (−3%) | $8.09 | $27K | -33.5% | — |
| Feb 4SEC | Ian HodgsonCOO | Sell | 2,41551,927 held (−4%) | $8.09 | $20K | -33.5% | — |
| Dec 15SEC | Bihua Chen10% Owner | Sell | 30,0292,344,971 held (−1%) | $11.46 | $344K | -53.1% | — |
| Oct 27SEC | Yuval CohenCEO | Sell Plan | 18,660138,187 held (−12%) | $17.01 | $317K | -68.4% | — |
| Oct 27SEC | Sean F. MoranCFO | Sell Plan | 12,98173,313 held (−15%) | $17.02 | $221K | -68.4% | — |
| Oct 27SEC | Yuval CohenCEO | Sell Plan | 8,973138,187 held (−6%) | $17.14 | $154K | -68.6% | — |
| Oct 21SEC | Anne AltmeyerDirector | Sell Plan | 1,0606,191 held (−15%) | $20.50 | $22K | -73.8% | — |
Insiders at Corbus Pharmaceuticals Holdings, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Yuval CohenCEO | — | $750K | Aug 10, 2026 | — |
| Nishant C SaxenaChief Business Officer | $126K | — | Aug 12, 2026 | — |
| Sean F. MoranCFO | — | $378K | Aug 10, 2026 | — |
| Bihua Chen10% Owner | — | $344K | Dec 15, 2025 | — |
| Dominic SmethurstChief Medical Officer | — | $77K | Mar 4, 2026 | — |
| Anne AltmeyerDirector | — | $41K | Jun 11, 2026 | — |
| John Kenneth JenkinsDirector | — | $38K | Jun 11, 2026 | — |
| Ian HodgsonCOO | — | $26K | Feb 18, 2026 | — |
| Winston KungDirector | — | $16K | Jun 11, 2026 | — |
| Yong BenDirector | — | $16K | Sep 15, 2026 | — |
CRBP stock: common questions
Are Corbus Pharmaceuticals Holdings, Inc. insiders buying CRBP stock?
In the past 12 months, 1 insiders reported open-market purchases of CRBP worth $126K. The latest was Chief Business Officer Nishant C Saxena bought $25K of CRBP at $9.63.
Are Corbus Pharmaceuticals Holdings, Inc. insiders selling CRBP stock?
9 insiders reported sales worth $1.7M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is CRBP's 52-week range?
Over the past year CRBP has traded between $5.27 and $19.36. It last closed at $5.38 on Oct 9, 2026.